A new trading day began on Monday, with Ocular Therapeutix Inc (NASDAQ: OCUL) stock price down -17.02% from the previous day of trading, before settling in for the closing price of $7.14. OCUL’s price has ranged from $4.06 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 125.96% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 4.67%. With a float of $132.39 million, this company’s outstanding shares have now reached $157.22 million.
In an organization with 267 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.58%, operating margin of -230.12%, and the pretax margin is -284.02%.
Ocular Therapeutix Inc (OCUL) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 15.79%, while institutional ownership is 73.34%. The most recent insider transaction that took place on Feb 24 ’25, was worth 147,533. In this transaction an insider of this company sold 21,475 shares at a rate of $6.87, taking the stock ownership to the 3,520,318 shares. Before that another transaction happened on Feb 24 ’25, when Company’s Chief Scientific Officer sold 3,061 for $6.87, making the entire transaction worth $21,029. This insider now owns 265,998 shares in total.
Ocular Therapeutix Inc (OCUL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.67% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Here are Ocular Therapeutix Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.24 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.39 million. That was better than the volume of 0.98 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.55%. Additionally, its Average True Range was 0.41.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 1.02%, which indicates a significant decrease from 3.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.42% in the past 14 days, which was higher than the 58.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.88, while its 200-day Moving Average is $8.24. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $6.76. Second resistance stands at $7.60. The third major resistance level sits at $8.05. If the price goes on to break the first support level at $5.48, it is likely to go to the next support level at $5.03. Assuming the price breaks the second support level, the third support level stands at $4.19.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
With a market capitalization of 931.51 million, the company has a total of 157,217K Shares Outstanding. Currently, annual sales are 58,440 K while annual income is -80,740 K. The company’s previous quarter sales were 15,430 K while its latest quarter income was -36,490 K.
